A novel immune‑related lncRNA as a prognostic biomarker in HER2<sup>+</sup> breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A novel immune‑related lncRNA as a prognostic biomarker in HER2⁺ breast cancer

Published:2024-04-16 Issue:6 Volume:27 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Li Xinwei¹,Meng Yue²,Gu Bing¹

Affiliation:

1. Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, P.R. China

2. Department of Clinical Laboratory, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, P.R. China

Publisher

Spandidos Publications

Reference35 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

2. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study;Carey;JAMA,2006

3. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US;Cronin;Cancer Invest,2010

4. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

5. From discovery to function: The expanding roles of long noncoding RNAs in physiology and disease;Sun;Endocr Rev,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP